nference’s Post

I am proud to share the findings of this research study titled, "Treatment Patterns in Women with Postmenopausal Osteoporosis Using Abaloparatide: A Real-World Observational Study," as an example of how to generate data outside of a clinical trial to support your product value proposition. Sometimes, it is not feasible to collect all the necessary data in a randomized controlled clinical trial due to time and resource constraints. In this example, we initiated a real-world study shortly after launch to gather data on patient experience with abaloparatide, an osteoanabolic agent administered as a daily subcutaneous injection for treatment of patients at high risk for osteoporotic fractures. We collaborated with eight academic and community practice settings across the country through MSL engagement to collect data. The study included a patient survey and an electronic Case Report Form to gather information on disease and treatment history, including prescribing decisions and patient perspective of disease and its management. A follow-up study was carried out, which incuded patients from six sites who reconsented, to further evaluate treatment patterns and outcomes. Primary data collection in this study allowed for a broader capture of data typically not available through secondary data sources (i.e., claims databases or electronic health records). Of note is the importance of regular monitoring and follow-up in patient satisfaction, treatment persistence and the potential for improved outcomes. This is particularly important in this patient population given the significant disease burden associated with osteoporotic related fracture including functional decline, loss of independence, caregiver burden and long-term care costs. Congratulations to all co-authors and research collaborators #RWE #Starbiopharmaconsulting #DeboraGold #TammyBeckett #ChadDeal #AndrewJames #MahshidMohseni #LenyPearman #TomBailey #abigailMcMillan #YameiWang #JacquelineMKernaghan #JohnCaminis Gold, D.T., Beckett, T., Deal, C. et al. Treatment patterns in women with postmenopausal osteoporosis using abaloparatide: a real-world observational study. Osteoporos Int (2024). https://rdcu.be/dFJPM

Gastroenterology research is hot right now. Between the rapidly evolving IBD market, recent approvals of novel obesity therapeutics, and the race to cure NASH, real-world GI data is needed now more than ever. See how Lynx.MD and Gastro Health have partnered to create one of the largest repositories of real-world structured and unstructured GI-related medical datasets: https://lnkd.in/gRQZb6fT Looking forward to learning more about how Lynx.MD can accelerate your GI research and improve the quality of GI care.

This partnership between Lynx.MD and GastroHealth is driving innovation by leveraging RWD. I am most excited by the work being done to accelerate AI with respect to medical imaging. Historically, it has been difficult for imaging data to be accessed because of its complexity and unstructured nature. Proud of the work being done by Lynx.MD to overcome these challenges. #innovation #rwd #ai #medicalimaging

📢 New case study! Melbourne-based #biotech Atmo Biosciences was awarded funding from our BioMedTech Horizons (BMTH) program to develop its world’s first, single-use ingestible gas-sensing capsule. Many individuals worldwide suffer from #gastrointestinal (GI) disorders, which incur debilitating symptoms, significant morbidity and high healthcare costs. Irritable bowel syndrome (IBS), for example, affects 25 to 45 million people in the US and two to five million people in Australia. Other common disorders include motility abnormalities, small intestinal bacterial overgrowth (SIBO), which is often associated with #IBS, and inflammatory bowel disease (IBD). Gas sensing from within the #gut offers an accurate method for diagnosing common #GI conditions, but to date there have been no convenient tools available to clinicians. Find out how Atmo Biosciences is helping to revolutionise gut health #diagnosis with its pioneering gas-sensing gut #capsule. Malcolm Hebblewhite | Sue Dafnias | Kyle Berean | Hon. Jaala Pulford | Stuart Dignam | Gerard Gibbs | Elizabeth Stares | Duncan Macinnis | RMIT University | Department of Industry, Science and Resources | Monash University | Breakthrough Victoria | #IBD #guthealth #SIBO #motility #medtech #pioneering #groundbreaking #innovation #innovate

Diaceutics PLC have announced an open invitation to all stakeholders in precision medicine to join a collaboration to address the economic barriers preventing patient access to life-changing precision medicines at an online event on 1st of May. The 'Precision Medicine Practice Gaps Economic, Policy and Operational Solutions Forum' was established in 2023 to progress research undertaken by Diaceutics and The Personalized Medicine Coalition (PMC) which highlighted that 64.4% of a NSCLC patients in the US may not receive the best treatment for their disease. The forum was established to urgently address the specific economic gaps limiting the advancement of precision medicine and to enable every patient to get the treatment they deserve.  Co-chaired by Susanne Munksted, Chief Precision Medicine Officer at Diaceutics, and Denny Van Liew, Board Member Emeritus at the PMC and veteran Solution Architect and Life Sciences Senior Advisor at Red Nucleus, the forum is composed of leading experts in precision medicine. The solutions and recommendations proposed will be shared for discussion at a virtual global summit this May 1st.  Find out more and register at https://lnkd.in/e5-uyjZv

Cryoneurolysis versus radiofrequency ablation outcome on pain experience in chronic low back pain (COPE): a single-blinded randomised controlled trial Cryoneurolysis versus Radiofrequency Ablation for Chronic Low Back Pain Key Findings: A study compared cryoneurolysis and radiofrequency (RF) with a placebo for patients with chronic low back pain. The primary goal was to assess patient global impression of change (PGIC), pain intensity, function, and quality of life over a 1-year period. Study Design: The research was a single-blinded, placebo-controlled randomized trial conducted at a single center. It included consenting adults over 18 years old with chronic low back pain and a positive response to a diagnostic medial branch block. Interventions: 120 patients were randomly assigned to receive cryoneurolysis, RF, or a placebo of the medial branch nerves. All groups also received physical therapy after 4 weeks. Outcomes: The primary outcome measured patient global impression of change (PGIC) at 4 weeks after the intervention. Secondary outcomes included pain intensity, quality of life, disability, depression, and catastrophizing, measured at 4 weeks, 3, 6, and 12 months. Results: There was no significant difference in PGIC at 4 weeks between cryoneurolysis and placebo, or RF and placebo. However, at the 6-month follow-up, cryoneurolysis showed a significant improvement in PGIC. No significant differences were found in the secondary follow-up endpoints. Conclusions: Denervation of the medial branch nerve by cryoneurolysis or RF did not demonstrate significant improvement in PGIC, pain intensity, function, and quality of life in patients with chronic low back pain at short-term or long-term follow-up. Practical Solutions: Clinical trials are essential for developing safe and effective treatments. Our AI-driven platform, DocSym, consolidates clinical protocols and research into an easily accessible knowledge base for clinicians. Additionally, our mobile apps support scheduling, monitoring treatments, and telemedicine, streamlining operations and improving patient outcomes. https://lnkd.in/erHYywXu #ClinicalTrials #AIinHealthcare #MedicalAI #HealthTech #DigitalHealth #PatientCareAI #AIResearch #MedicalInnovation #BioTech #AIforGood #HealthcareData #AIinMedicine #PharmaAI #ClinicalData #HealthAI #AIHealthSolutions #PrecisionMedicine #AIandHealth #ClinicalAnalytics #AIDiagnostics

A prospective randomized controlled clinical trial investigating the efficacy of low-dose olanzapine in preventing nausea and vomiting associated with oxaliplatin-based and irinotecan-based chemotherapy Study Title A study on the effectiveness of low-dose olanzapine in preventing nausea and vomiting during chemotherapy Objective To evaluate the effectiveness of 5 mg olanzapine in preventing chemotherapy-induced nausea and vomiting (CINV) in female patients with gastrointestinal tract tumors undergoing moderately emetogenic chemotherapy (MEC). Methods Patients received either 5 mg olanzapine with palonosetron and dexamethasone or a standard two-drug combination of dexamethasone and palonosetron. The study assessed total protection rates, total control rates, complete remission rates, and quality of life, as well as collected adverse events data. Results 1) The olanzapine group showed higher total protection rates compared to the control group in both the entire age group and the subgroup aged 60 years and above. 2) The olanzapine group exhibited superior acute phase protection rates in both age brackets compared to the control group. Quality of life was also better in the olanzapine group, with improved appetite and higher incidence of drowsiness. Conclusion Olanzapine can improve CINV induced by MEC regimen in female patients of all age groups, including the elderly, and enhance their quality of life. Clinical Trial Registration Clinical Trial Registration, identifier: ChiCTR20000368269, 25/08/2020 Practical Solutions and Value Clinical trials are crucial for developing safe treatments. Our AI-driven platform, DocSym, consolidates clinical standards and research for easy access. Streamlining operations is essential in healthcare, and our mobile apps support scheduling, monitoring treatments, and telemedicine, enhancing patient care and expanding services digitally. AI can improve workflows and patient outcomes, reducing paper routines. Learn more at aidevmd.com. https://lnkd.in/gkny3w9g #ClinicalTrials #AIinHealthcare #MedicalAI #HealthTech #DigitalHealth #PatientCareAI #AIResearch #MedicalInnovation #BioTech #AIforGood #HealthcareData #AIinMedicine #PharmaAI #ClinicalData #HealthAI #AIHealthSolutions #PrecisionMedicine #AIandHealth #ClinicalAnalytics #AIDiagnostics

Best Precision Medicine for Better Healthcare 2024: Revolutionizing Patient Treatment Understanding Precision Medicine: A Paradigm Shift in Healthcare The Role of Genomics in Precision Medicine Applications of Precision Medicine in Healthcare Advancements in Pharmacogenomics: Optimizing Drug Therapy Precision Medicine in Chronic Disease Management The Job of Computerized reasoning (artificial intelligence) in the Accuracy of Medication Challenges and Opportunities in Precision Medicine The Future of Precision Medicine: Towards Personalized Healthcare #foryou #viral #trending #healthcare #health #healthandwellness #genomics #precisionmedicine #drugs #usa #womenhealth #follow #share To Read More.... https://bit.ly/43zkyVH

I am pleased to share our recently published manuscript, as part of the precision medicine working group of the Crohn's & Colitis Foundation "Challenges in IBD Research 2024: Precision Medicine" https://lnkd.in/ez3ybbPv This comprehensive document highlights significant gaps in inflammatory bowel disease (IBD) research and offers actionable strategies to address them. Grateful for the opportunity to be part of this multidisciplinary collaboration that made this work possible! "Precision medicine is the practice of getting the most suitable drug or treatment option to each individual patient at the right time. In Crohn’s disease and ulcerative colitis, we need to learn more about the diversity of patients to deliver precision medicine." #IBDResearch #PrecisionMedicine #Biomarkers #CrohnsAndColitisFoundation #HealthcareInnovation

I may ruffle some feathers but we need to start advocating for the patient when it comes to hyperbaric medicine! Keep in mind mild hyperbarics can be done in a hard shell chamber at high pressure! If the patient is supplied oxygen with a nasal cannula, simple mask, partial non rebreather, or full non rebreather it is mild hbot! Let’s route out the doctors and practioners making these claims, taking short cuts, and providing patients with sub standard care! Unraveling the Placebo Effect: From Endemic to Epidemic - Mild Hyperbaric Oxygen Therapy (Low Dose Oxygen) Threatens Legitimate Medical Hyperbaric Oxygen In the realm of healthcare, the placebo effect and pseudoscience intersect in intriguing ways, particularly evident in the case of mild hyperbaric oxygen therapy (mHBOT). While historically, placebos have influenced patient outcomes even in the absence of active treatment, mHBOT stands as a contemporary example of a modality whose purported benefits may largely be attributed to the placebo effect rather than scientifically proven mechanisms. #PlaceboResearch #Pseudoscience Mild hyperbaric oxygen therapy, often marketed as a panacea for various ailments, lacks robust clinical evidence to support its efficacy. Despite claims of improved cognitive function, accelerated wound healing, and enhanced athletic performance, scientific studies have failed to demonstrate consistent, reproducible results. Instead, the observed effects of mHBOT may be better explained by the placebo effect – the psychological phenomenon wherein sham interventions lead to perceived improvements in a patient's condition. #EvidenceBasedMedicine #ClinicalResearch This parallel between placebo effects and pseudoscience is particularly evident in mHBOT, where patients' expectations and beliefs about the therapy may significantly influence their perceived outcomes. The ritualistic nature of undergoing mHBOT sessions, coupled with anecdotal testimonials and marketing hype, can amplify placebo responses, leading patients to attribute subjective improvements to the treatment itself. #PatientExpectations #AnecdotalEvidence However, the absence of rigorous scientific evidence supporting the efficacy of mHBOT raises ethical concerns. Patients may be misled into pursuing expensive and potentially risky treatments with little to no proven benefit, emphasizing the importance of critical thinking and evidence-based practice in healthcare. #EthicalHealthcare #CriticalThinking In conclusion, the case of mild hyperbaric oxygen therapy serves as a poignant reminder of the intricate interplay between placebo effects and pseudoscience in healthcare. By unraveling the significance of placebo responses and scrutinizing purported treatments with scientific rigor, we can safeguard against the exploitation of patient vulnerabilities and uphold the principles of ethical and evidence-based care. #HealthcareEthics #ScientificRigor https://lnkd.in/dpZhEW_t